Reinventing the fight against bacteria,
one phage at a time.

Bacteriophages are increasingly being investigated as treatments for antibiotic-resistant bacterial infections, but their potential extends far beyond antimicrobial therapy. At the Massachusetts Institute of Technology (MIT), a research team led by Professor Angela Belcher has demonstrated how genetically engineered bacteriophages can become programmable nanovaccines capable of stimulating powerful antitumor immune responses. In a study published on August 27, 2025, in Advanced Materials , Shengnan Huang, Angela Belcher and colleagues developed an M13 bacteriophage-based cancer vaccine that increased neoantigen-specific CD8⁺ T-cell responses by approximately 24-fold and, when combined with anti-PD-1 immunotherapy, achieved complete regression of established colorectal tumors in 75% of treated mice . Professor Angela Belcher demonstrates the genetically programmable M13 bacteriophage during MIT's 2023 Dresselhaus Lecture. Her laboratory has since developed M13-based cancer nanovacci...

On October 20, 2026, American biotechnology company Radical Numerics announced that bacteriophages designed using its Omnii-1 artificial intelligence model had been administered to a human patient with an antibiotic-resistant Escherichia coli infection. According to the company, the investigational phage cocktail included AI-designed variants of bacteriophage T7 and was administered under a single-patient expanded-access authorization from the U.S. Food and Drug Administration (FDA). The announcement represents a potentially important development at the intersection of generative artificial intelligence, synthetic biology and personalized phage therapy. While genome language models have already demonstrated their ability to design functional bacteriophages in laboratory experiments, Radical Numerics reports taking a further step by incorporating AI-engineered viral variants into a preparation administered to a patient. Omnii-1, Radical Numerics' multimodal genome language model, ha...

Belgian biotechnology company Inteliphage is preparing to expand its bacteriophage manufacturing capabilities at BioPark Charleroi, taking over 1,200 m² of existing cleanroom facilities to support the development and production of phages for patients with difficult-to-treat bacterial infections. Announced on October 20, 2026, the expansion represents an important step in the company's strategy to connect rapid phage susceptibility testing with the supply of quality-controlled therapeutic preparations. The new facilities comprise five cleanrooms previously occupied by the American pharmaceutical services group Catalent. Inteliphage has taken over the premises since September 2026, avoiding the need to construct an entirely new manufacturing building. The company currently employs six people and intends to expand its workforce to approximately 30 as its activities develop. Inteliphage expands its phage manufacturing ambitions in Belgium. COO and co-founder Guillaume de Viron (left) a...

On October 20, 2026, French biotechnology company Phagos announced the public release of CAPHARD , a genomic artificial intelligence model designed to predict interactions between bacteriophages and bacterial strains. Accessible through Hugging Face, the platform enables researchers to evaluate the compatibility of sequenced phages with bacterial isolates or search a reference collection of 832 bacteriophages for candidates potentially capable of infecting a particular strain. The release follows several years of development supported by European supercomputing resources and represents a new application of large language models to phage discovery, microbiology and antimicrobial resistance research. The identification of suitable bacteriophages remains one of the principal technical challenges in developing personalized phage therapies. Unlike conventional broad-spectrum antibiotics, many phages exhibit highly restricted host ranges, sometimes distinguishing between closely related bact...

Bacteriophages are beginning to move from experimental plant pathology into commercial crop protection. Several phage-based bactericides are now registered in the United States, China has registered its first crop bacteriophage pesticide, European growers have received temporary access to phage products against fire blight, and additional programmes are progressing through regulatory development in North America, Europe and Latin America. The market remains much smaller than the markets for conventional pesticides or microbial biocontrol products. It is also easy to misunderstand. A company announcing a distribution agreement does not necessarily mean that its product is legally authorized for use in that country. A successful field trial does not equal registration, and an emergency authorization valid for a few months in one European country is not the same as an EU-wide approval. This guide separates commercially registered products from temporary authorizations and development prog...